- Home
- KITT vs IGC Comparison
KITT vs IGC Comparison
Compare KITT & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KITT
- IGC
- Stock Information
- Founded
- KITT 2014
- IGC 2005
- Country
- KITT United States
- IGC United States
- Employees
- KITT N/A
- IGC N/A
- Industry
- KITT Industrial Machinery/Components
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- KITT Industrials
- IGC Health Care
- Exchange
- KITT Nasdaq
- IGC Nasdaq
- Market Cap
- KITT 36.4M
- IGC 39.8M
- IPO Year
- KITT N/A
- IGC N/A
- Fundamental
- Price
- KITT $3.80
- IGC $0.42
- Analyst Decision
- KITT
- IGC Strong Buy
- Analyst Count
- KITT 0
- IGC 2
- Target Price
- KITT N/A
- IGC $4.00
- AVG Volume (30 Days)
- KITT 362.6K
- IGC 1.4M
- Earning Date
- KITT 08-11-2025
- IGC 08-14-2025
- Dividend Yield
- KITT N/A
- IGC N/A
- EPS Growth
- KITT N/A
- IGC N/A
- EPS
- KITT N/A
- IGC N/A
- Revenue
- KITT $3,082,232.00
- IGC $1,327,000.00
- Revenue This Year
- KITT $2,936.06
- IGC $15.26
- Revenue Next Year
- KITT N/A
- IGC $3.41
- P/E Ratio
- KITT N/A
- IGC N/A
- Revenue Growth
- KITT N/A
- IGC 24.95
- 52 Week Low
- KITT $3.75
- IGC $0.25
- 52 Week High
- KITT $54.36
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- KITT 23.19
- IGC 57.28
- Support Level
- KITT $6.84
- IGC $0.40
- Resistance Level
- KITT $10.35
- IGC $0.47
- Average True Range (ATR)
- KITT 0.86
- IGC 0.04
- MACD
- KITT -0.40
- IGC 0.00
- Stochastic Oscillator
- KITT 0.15
- IGC 49.20
About KITT Nauticus Robotics Inc.
Nauticus Robotics Inc develops fully electric autonomous robotic solutions for subsea applications. The company's business model includes using robotic systems for service, selling vehicles and components, and licensing related software to both the commercial and defense business sectors. The company's addressable markets include upstream, midstream, and downstream oil and gas, defense, offshore renewables, seafloor telecommunications, aquaculture, port security, oceanographic research, and subsea mining.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.